LPTX

Leap Therapeutics Stock Price

1.88
0.00 (0.0%)
1.88
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Leap Therapeutics Inc LPTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.88 07:00:00
Close Price Low Price High Price Open Price Previous Close
1.88
Bid Price Ask Price Spread News
1.86 1.88 0.02 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
6 398 $ 1.88 $ 748 466,654 0.5728 - 3.18
Last Trade Time Type Quantity Stock Price Currency
09:01:25 2 $ 1.87 USD

Leap Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 112.16M 59.66M 41.02M $ - $ - -1.49 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Leap Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical LPTX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.932.041.851.93439,542-0.05-2.59%
1 Month1.782.111.651.89448,6550.105.62%
3 Months2.112.271.651.97745,948-0.23-10.9%
6 Months1.253.101.202.06584,5210.6350.4%
1 Year1.473.180.57281.94561,7790.4127.89%
3 Years5.6210.250.57282.34358,653-3.74-66.55%
5 Years6.1110.250.57282.40297,789-4.23-69.23%

Leap Therapeutics Description

Leap Therapeutics Inc is a biopharmaceutical company. The company is acquiring and developing novel therapeutics at the leading edge of cancer biology. Its programs are monoclonal antibodies that target key cellular pathways that enable cancer to grow and spread and specific mechanisms that activate the body's immune system to identify and attack cancer. Leap has two clinical stage programs: DKN-01 and TRX518. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1, or DKK1, a protein that regulates important cell signaling pathways, known as the Wnt pathways. TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR, a receptor found on the surface of a wide range of immune cells.


Your Recent History
NASDAQ
LPTX
Leap Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.